Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research

James M. Foran, Steven Z. Pavletic, Brent R. Logan, Manza A. Agovi-Johnson, Waleska S. Pérez, Brian J. Bolwell, Martin Bornhäuser, Christopher N. Bredeson, Mitchell S. Cairo, Bruce M. Camitta, Edward A. Copelan, Jason Dehn, Robert P. Gale, Biju George, Vikas Gupta, Gregory A. Hale, Hillard M. Lazarus, Mark R. Litzow, Dipnarine Maharaj, David I. MarksRodrigo Martino, Richard Maziarz, Jacob M. Rowe, Philip A. Rowlings, Bipin N. Savani, Mary Lynn Savoie, Jeffrey Szer, Edmund K. Waller, Peter H. Wiernik, Daniel J. Weisdorf

Research output: Contribution to journalArticle

15 Scopus citations


The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n= 242) or reduced-intensity conditioning (RIC; n= 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% confidence interval [CI], 38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival was 22% (95% CI, 18%-27%). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P 18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P

Original languageEnglish (US)
Pages (from-to)1102-1108
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number7
Publication statusPublished - Jul 2013



  • Acute myelogenous leukemia
  • Allogeneic
  • Autologous
  • Transplantation
  • Unrelated donor

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this